88 related articles for article (PubMed ID: 31978780)
21. Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
López-Valero I; Torres S; Salazar-Roa M; García-Taboada E; Hernández-Tiedra S; Guzmán M; Sepúlveda JM; Velasco G; Lorente M
Biochem Pharmacol; 2018 Nov; 157():275-284. PubMed ID: 30125556
[TBL] [Abstract][Full Text] [Related]
22. A peptide derived from apoptin inhibits glioma growth.
Zhang L; Zhao H; Cui Z; Lv Y; Zhang W; Ma X; Zhang J; Sun B; Zhou D; Yuan L
Oncotarget; 2017 May; 8(19):31119-31132. PubMed ID: 28415709
[TBL] [Abstract][Full Text] [Related]
23. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Wu M; Fan Y; Lv S; Xiao B; Ye M; Zhu X
Drug Deliv; 2016 Oct; 23(8):2720-2725. PubMed ID: 26203691
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells.
Zhang L; Peterson TE; Lu VM; Parney IF; Daniels DJ
PLoS One; 2019; 14(7):e0220569. PubMed ID: 31361777
[TBL] [Abstract][Full Text] [Related]
25. Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Chen L; Zeng D; Xu N; Li C; Zhang W; Zhu X; Gao Y; Chen PR; Lin J
ACS Appl Mater Interfaces; 2019 Nov; 11(45):41889-41897. PubMed ID: 31615203
[TBL] [Abstract][Full Text] [Related]
26. The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo.
Kübler J; Kirschner S; Hartmann L; Welzel G; Engelhardt M; Herskind C; Veldwijk MR; Schultz C; Felix M; Glatting G; Maier P; Wenz F; Brockmann MA; Giordano FA
Oncotarget; 2016 Jul; 7(29):45500-45512. PubMed ID: 27275537
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Branle F; Lefranc F; Camby I; Jeuken J; Geurts-Moespot A; Sprenger S; Sweep F; Kiss R; Salmon I
Cancer; 2002 Aug; 95(3):641-55. PubMed ID: 12209758
[TBL] [Abstract][Full Text] [Related]
28. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
[TBL] [Abstract][Full Text] [Related]
29. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
31. Highly efficacious and specific anti-glioma chemotherapy by tandem nanomicelles co-functionalized with brain tumor-targeting and cell-penetrating peptides.
Zhu Y; Jiang Y; Meng F; Deng C; Cheng R; Zhang J; Feijen J; Zhong Z
J Control Release; 2018 May; 278():1-8. PubMed ID: 29596873
[TBL] [Abstract][Full Text] [Related]
32. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Kim JT; Kim JS; Ko KW; Kong DS; Kang CM; Kim MH; Son MJ; Song HS; Shin HJ; Lee DS; Eoh W; Nam DH
Oncol Rep; 2006 Jul; 16(1):33-9. PubMed ID: 16786120
[TBL] [Abstract][Full Text] [Related]
33. The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma.
Lu J; Zhuang Z; Song DK; Mehta GU; Ikejiri B; Mushlin H; Park DM; Lonser RR
J Neurosurg; 2010 Aug; 113(2):225-33. PubMed ID: 20001590
[TBL] [Abstract][Full Text] [Related]
34. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
Kumari S; Ahsan SM; Kumar JM; Kondapi AK; Rao NM
Sci Rep; 2017 Jul; 7(1):6602. PubMed ID: 28747713
[TBL] [Abstract][Full Text] [Related]
35. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
36. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model.
Ugur HC; Ramakrishna N; Bello L; Menon LG; Kim SK; Black PM; Carroll RS
J Neurooncol; 2007 Jul; 83(3):267-75. PubMed ID: 17310267
[TBL] [Abstract][Full Text] [Related]
37. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Lee DJ; Sharma N; Dubeau L; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2014 Aug; 13(8):2004-17. PubMed ID: 24994771
[TBL] [Abstract][Full Text] [Related]
38. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
39. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
40. Antiglioma activity of GoPI-sugar, a novel gold(I)-phosphole inhibitor: chemical synthesis, mechanistic studies, and effectiveness in vivo.
Jortzik E; Farhadi M; Ahmadi R; Tóth K; Lohr J; Helmke BM; Kehr S; Unterberg A; Ott I; Gust R; Deborde V; Davioud-Charvet E; Réau R; Becker K; Herold-Mende C
Biochim Biophys Acta; 2014 Aug; 1844(8):1415-26. PubMed ID: 24440405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
